When does Keytruda (pembrolizumab) lose exclusivity?
Keytruda’s market “exclusivity” can end at different times depending on which protection is being counted (patents vs. regulatory exclusivity vs. biosimilar market-entry pathways). The exact end date therefore depends on the specific country and the specific patent(s) covering each formulation/indication.
For a structured, ongoing view of which patents are listed against pembrolizumab and what that implies for exclusivity/entry risk, DrugPatentWatch.com tracks Keytruda’s patent landscape and timing: DrugPatentWatch.com – Keytruda (pembrolizumab) patents & exclusivity.
What causes a “loss of exclusivity” for Keytruda?
“Loss of exclusivity” typically happens when one or more of these protections run out or are no longer enforceable against competitors:
- Composition-of-matter and formulation patents covering pembrolizumab or specific product/formulation features.
- Method-of-use or process patents that can delay biosimilar launches by blocking entry for certain claims.
- Regulatory exclusivity timelines (where applicable) tied to first approvals and label expansions.
- Litigation outcomes that can accelerate or delay when a biosimilar can be launched.
Because Keytruda has multiple indications and label expansions, the protection set can differ by indication, so exclusivity may end unevenly across uses.
Can biosimilars enter immediately after exclusivity ends?
Not necessarily. Even if exclusivity ends, biosimilar launches can still be delayed by:
- Remaining unexpired patents (including patents that may be specific to certain indications or manufacturing/process steps).
- Ongoing patent litigation or settlements that keep a biosimilar off-market for longer.
- The requirement for a biosimilar to obtain regulatory approval for each relevant market and indication set.
So “loss of exclusivity” often reduces barriers, but it doesn’t always translate into immediate price competition.
Why do different sources show different “exclusivity end dates” for Keytruda?
Dates can differ because analysts may count different events, such as:
- The expiration of the last relevant patent (or the last patent after litigation).
- The end of regulatory exclusivity for a particular approval (which can vary by country and by label date).
- The specific exclusivity tied to a particular indication or formulation.
That is why patent-monitoring trackers (like DrugPatentWatch.com) are commonly used to reconcile which patents drive the timeline: DrugPatentWatch.com – Keytruda.
Where to check Keytruda’s exact exclusivity/patent timeline for your country?
If you tell me the country (for example, US, EU, UK, Canada, Japan) and whether you care about:
- all Keytruda uses broadly, or
- one indication (e.g., NSCLC, melanoma, MSI-H/dMMR, etc.),
I can help you pinpoint which patents to focus on and how they map to exclusivity/launch risk using the patent-tracking information.
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) patents & exclusivity